Back to Journals » Drug Design, Development and Therapy
Drug Design, Development and Therapy
ISSN: 1177-8881

Editor-in-Chief: Prof. Dr. Frank Boeckler
An international, peer-reviewed, open access journal that spans the spectrum of drug design and development through to clinical applications. The journal is characterized by the rapid reporting of application notes, reviews, original research and clinical studies in all therapeutic areas. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines will be a feature of the journal.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Articles:
- View all (3551)
- Volume 16, 2022 (111)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Latest articles:
- 5 records -
6-Methoxyflavone and Donepezil Behavioral Plus Neurochemical Correlates in Reversing Chronic Ethanol and Withdrawal Induced Cognitive Impairment
Arif M, Rauf K, Rehman NU, Tokhi A, Ikram M, Sewell RD
Drug Design, Development and Therapy 2022, 16:1573-1593
Published Date: 28 May 2022
Ropivacaine with Dexmedetomidine or Dexamethasone in a Thoracic Paravertebral Nerve Block Combined with an Erector Spinae Plane Block for Thoracoscopic Lobectomy Analgesia: A Randomized Controlled Trial
Yang J, Zhao M, Zhang XR, Wang XR, Wang ZH, Feng XY, Lei YJ, Zhang JW
Drug Design, Development and Therapy 2022, 16:1561-1571
Published Date: 26 May 2022

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP


Wang L
Drug Design, Development and Therapy 2022, 16:1547-1559
Published Date: 25 May 2022
Reduced the Food Effect and Enhanced the Oral Bioavailability of Ivacaftor by Self-Nanoemulsifying Drug Delivery System (SNEDDS) Using a New Oil Phase
Miao Y, Zhao S, Zuo J, Sun J, Wang J
Drug Design, Development and Therapy 2022, 16:1531-1546
Published Date: 23 May 2022
“PFH/AGM-CBA/HSV-TK/LIPOSOME-Affibody”: Novel Targeted Nano Ultrasound Contrast Agents for Ultrasound Imaging and Inhibited the Growth of ErbB2-Overexpressing Gastric Cancer Cells
Zhou H, Liu H, Zhang Y, Xin Y, Huang C, Li M, Zhao X, Ding P, Liu Z
Drug Design, Development and Therapy 2022, 16:1515-1530
Published Date: 18 May 2022